Complete separation of benefit and risk information lacks appropriate prominence

DisputedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

FDA treats complete separation of benefit and risk information in a print piece — for example, presenting several pages of benefits before any risks — as a lack of appropriate prominence. This is the complete-separation application of the same-parts recommendation in US-FB-015: risk information should generally appear in the same parts of the piece as the benefits.

Check

Review the structure of the print piece for complete separation of benefit and risk content, i.e., risk information confined to a distinct, separate portion of the piece rather than appearing in the same parts as the benefits. A multi-page piece presenting several benefit-only pages before any risk content appears is the paradigm instance, but any structure achieving complete separation should be flagged.

Escalate when

When benefit and risk information appear in fully separate portions of the piece and it is unclear whether the separation rises to the level of a lack of appropriate prominence.

Where this comes from

Section III.C.1, Overall Location of Risk Information · page 19. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… be included in the main part of a piece. If the omission of risk information in any part of a piece makes that part of the piece false or misleading, the problem cannot be corrected simply by including the risk information in a separate part of the piece. To be comparably prominent to benefit information, risk information should generally appear in the same parts of the piece as the benefits. Complete separation of benefit and risk information (e.g., presenting several pages of benefits before any risks) is one example of a lack of appropriate prominence. FDA will also look to see that risk information is not placed in such a way as to interfere with readers’ perceptions of the relative importance or utility of the information. \ Location of Risk Information within a Part of the Promotional Piece In addition to appearing with or near benefit presentations, risk information should appear as an integral part of the piece, just as benefit information does. For exa…

Open the original at page 19 on fda.gov ↗Read our full copy →

Document: FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: f5654ab082f6cd4408143f16…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Mediumprint

How this rule was checked

The verifier and drafter could not agree. Waiting for a human decision — not used in reviews.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The source sentence is about complete separation of benefit and risk information generally; 'presenting several pages of benefits before any risks' is introduced by 'e.g.' as one illustration of that separation. The rule drops the principle and promotes the illustration to be the entire rule, so the drafted rule is both narrower than the sentence it cites and, in the one respect it keeps, stronger than it: the source says such a structure 'is one example of a lack of appropriate prominence', whereas the rule declares that a print piece 'should not' do it.
- The subject matter is supported — FDA plainly treats complete separation as a prominence failure — so this is fixable rather than unfounded.
- As drafted the rule is also largely swallowed by US-FB-015 (risk information should generally appear in the same parts of the piece as the benefits); restated as the complete-separation case it is a meaningful application of that principle rather than a duplicate, which is the framing the revision should adopt.
- Medium scoping to print is justified: the sentence sits under 'III.C.1 Print Promotion' and the example is page-based.
- Judgment determinism is correct: 'several pages' and 'appropriate prominence' are not settled by a literal match, even though page order itself is observable.
- Authority 'guidance' is correct; the quote is a whole sentence; the locator 'Section III.C.1, Overall Location of Risk Information' is right; 'warning' severity is defensible.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — reject
claude-code:opus · 2026-09-21
Reviewer's reasons
- This duplicates US-FB-015 in the same packet. The rule text itself says it is 'the complete-separation application of the same-parts recommendation in US-FB-015'. Any piece that completely separates benefit and risk information already fails US-FB-015's recommendation that risk information generally appear in the same parts as the benefits, so this rule adds no independent check.
- The rule text also contains a cross-reference to another rule ID ('in US-FB-015'). That is a pipeline note, not a restatement of the source.
- The source sentence is FDA's example of the same-parts problem ('one example of a lack of appropriate prominence'). It belongs in US-FB-015's Check or Escalate text as the paradigm case, not in a separate rule.

Nearby rules

US-FB-014 US-FB-015